Literature DB >> 32597377

The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?

Josef Klhůfek1.   

Abstract

Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19. At the same time, ACE 2 expression decreases during COVID-19. Two seemingly contradictory relationships between the expression of ACE 2 and COVID-19 have been reported. Increased level of expression of ACE 2 may be a risk factor for the development of COVID-19 infection, while reduced ACE 2 expression during COVID-19 leads to acute respiratory distress syndrome. This article provides a comprehensive overview of available scientific knowledge about the role of ACE 2 in the pathogenesis of COVID-19, which is available up to current day. Also, it discusses unknown factors that we will have to reveal in order to understand the whole role of ACE 2 in the pathogenesis of COVID-19.

Entities:  

Keywords:  Covid-19; SARS-CoV-2; ace-inhibitors; angiotensin receptors blockers; angiotensin-converting enzyme 2; diabetes; elderly; hypertension; smoking

Mesh:

Substances:

Year:  2020        PMID: 32597377     DOI: 10.1080/17843286.2020.1786324

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  5 in total

Review 1.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 2.  COVID-19: Why does disease severity vary among individuals?

Authors:  Saeed Samadizadeh; Maha Masoudi; Mostafa Rastegar; Vahid Salimi; Mahsa Bataghva Shahbaz; Alireza Tahamtan
Journal:  Respir Med       Date:  2021-03-05       Impact factor: 4.582

3.  Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation.

Authors:  Mona Alshahawey; Mohamed Raslan; Nagwa Sabri
Journal:  Curr Res Transl Med       Date:  2020-09-06       Impact factor: 4.513

4.  COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.

Authors:  Anca Bobircă; Florin Bobircă; Ioan Ancuța; Anca Florescu; Mihai Bojincă; Alice Muscă; Dan Nicolae Florescu; Lucian Mihai Florescu; Romina Marina Sima; Alesandra Florescu; Anca Emanuela Mușetescu
Journal:  Life (Basel)       Date:  2022-01-06

5.  Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.

Authors:  Hozaifa Khalil Elsawah; Mohamed Ahmed Elsokary; Mahmoud Gamal Elrazzaz; Ahmed Hanei Elshafie
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.